DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

被引：72

作者：

Li, Dongwei ^{[1
]}

Poon, Kirsten Achilles ^{[1
]}

Yu, Shang-Fan ^{[1
]}

Dere, Randall ^{[1
]}

Go, MaryAnn ^{[1
]}

Lau, Jeffrey ^{[1
]}

Zheng, Bing ^{[1
]}

Elkins, Kristi ^{[1
]}

Danilenko, Dimitry ^{[1
]}

Kozak, Katherine R. ^{[1
]}

Chan, Pamela ^{[1
]}

Chuh, Josefa ^{[1
]}

Shi, Xiaoyan ^{[1
]}

Nazzal, Denise ^{[1
]}

Fuh, Franklin ^{[1
]}

McBride, Jacqueline ^{[1
]}

Ramakrishnan, Vanitha ^{[1
]}

de Tute, Ruth ^{[2
]}

Rawstron, Andy ^{[2
]}

Jack, Andrew S.

Deng, Rong ^{[1
,3
]}

Chu, Yu-Waye ^{[1
,3
]}

Dornan, David ^{[1
,3
]}

Williams, Marna ^{[1
]}

Ho, William ^{[1
]}

Ebens, Allen ^{[1
]}

Prabhu, Saileta ^{[1
]}

Polson, Andrew G. ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA USA

[2] Leeds Teaching Hosp, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England

[3] Univ York, HYMS, York YO10 5DD, N Yorkshire, England

来源：

MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 07期

关键词：

EPRATUZUMAB; CALICHEAMICIN; CHEMOTHERAPY; MALIGNANCIES; LINKER; TRIAL;

D O I：

10.1158/1535-7163.MCT-12-1173

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Antibody-drug conjugates (ADC), potent cytotoxic drugs linked to antibodies via chemical linkers, allow specific targeting of drugs to neoplastic cells. We have used this technology to develop the ADC DCDT2980S that targets CD22, an antigen with expression limited to B cells and the vast majority of non-Hodgkin lymphomas (NHL). DCDT2980S consists of a humanized anti-CD22 monoclonal IgG1 antibody with a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE), linked to the reduced cysteines of the antibody via a protease cleavable linker, maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl (MC-vc-PAB). We describe the efficacy, safety, and pharmacokinetics of DCDT2980S in animal models to assess its potential as a therapeutic for the treatment of B-cell malignancies. We did not find a strong correlation between in vitro or in vivo efficacy and CD22 surface expression, nor a correlation of sensitivity to free drug and in vitro potency. We show that DCDT2980S was capable of inducing complete tumor regression in xenograft mouse models of NHL and can be more effective than rituximab plus combination chemotherapy at drug exposures that were well tolerated in cynomolgus monkeys. These results suggest that DCDT2980S has an efficacy, safety, and pharmacokinetics profile that support potential treatment of NHL. (C) 2013 AACR.

引用

页码：1255 / 1265

页数：11

共 19 条

[1] B Cells Behaving Badly: A Better Basis to Behold Belligerence in B-Cell Lymphomas [J].

Bagg, Adam .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2011, :330-335

[2]

Barclay AN., 1997, LEUCOCYTE ANTIGEN FA

[3] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

[4] Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies [J].

DiJoseph, JF ;

Armellino, DC ;

Boghaert, ER ;

Khandke, K ;

Dougher, MM ;

Sridharan, L ;

Kunz, A ;

Hamann, PR ;

Gorovits, B ;

Udata, C ;

Moran, JK ;

Popplewell, AG ;

Stephens, S ;

Frost, P ;

Damle, NK .

BLOOD, 2004, 103 (05) :1807-1814

[5] Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma [J].

Dornan, David ;

Bennett, Fiona ;

Chen, Yvonne ;

Dennis, Mark ;

Eaton, Dan ;

Elkins, Kristi ;

French, Dorothy ;

Go, Mary Ann T. ;

Jack, Andrew ;

Junutula, Jagath R. ;

Koeppen, Hartmut ;

Lau, Jeffrey ;

McBride, Jacqueline ;

Rawstron, Andy ;

Shi, Xiaoyan ;

Yu, Nancy ;

Yu, Shang-Fan ;

Yue, Peng ;

Zheng, Bing ;

Ebens, Allen ;

Polson, Andrew G. .

BLOOD, 2009, 114 (13) :2721-2729

[6] Development of potent monoclonal antibody auristatin conjugates for cancer therapy [J].

Doronina, SO ;

Toki, BE ;

Torgov, MY ;

Mendelsohn, BA ;

Cerveny, CG ;

Chace, DF ;

DeBlanc, RL ;

Gearing, RP ;

Bovee, TD ;

Siegall, CB ;

Francisco, JA ;

Wahl, AF ;

Meyer, DL ;

Senter, PD .

NATURE BIOTECHNOLOGY, 2003, 21 (07) :778-784

[7] Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation [J].

Gopal, Ajay K. ;

Ramchandren, Radhakrishnan ;

O'Connor, Owen A. ;

Berryman, Robert B. ;

Advani, Ranjana H. ;

Chen, Robert ;

Smith, Scott E. ;

Cooper, Maureen ;

Rothe, Achim ;

Matous, Jeffrey V. ;

Grove, Laurie E. ;

Zain, Jasmine .

BLOOD, 2012, 120 (03) :560-568

[8]

Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]

[9] Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies [J].

Leonard, J. P. ;

Goldenberg, D. M. .

ONCOGENE, 2007, 26 (25) :3704-3713

[10] Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results [J].

Leonard, JP ;

Coleman, M ;

Ketas, JC ;

Chadburn, A ;

Furman, R ;

Schuster, MW ;

Feldman, EJ ;

Ashe, M ;

Schuster, SJ ;

Wegener, WA ;

Hansen, HJ ;

Ziccardi, H ;

Eschenberg, M ;

Gayko, U ;

Fields, SZ ;

Cesano, A ;

Goldenberg, DM .

CLINICAL CANCER RESEARCH, 2004, 10 (16) :5327-5334

← 1 2 →